App review
mySugr review: the integrated logbook with a regulated bolus advisor in select markets
mySugr is a Roche-owned diabetes self-management application that integrates glucose logging, carbohydrate logging, and a bolus calculator. In several European markets the bolus advisor is registered as a medical device. Carbohydrate counts in mySugr are user-entered or imported from a partner application; the application is not a photo-based estimator. For T1D and T2D users on insulin who want a single-screen logbook, mySugr is one of the most credible options in the segment.
At a glance
| Best for | T1D and insulin-treated T2D users who want an integrated logbook with regulated bolus support where available; users of Accu-Chek pumps. |
|---|---|
| Pricing | Free tier; Pro subscription approximately $3 per month or $28 per year (regional variation). |
| CGM integration | Accu-Chek devices, FreeStyle Libre (regional), Dexcom (regional), Apple Health |
| FDA status | The mySugr bolus calculator is registered as a medical device in select EU markets under MDR. In the United States, mySugr is distributed as a logbook; users should verify current FDA status before relying on any clearance claim. |
Strengths
- Integrated bolus calculator; in select EU markets, registered as a medical device under MDR.
- Strong glucose-logging workflow with CGM data import (Accu-Chek, FreeStyle Libre via partner integrations, Dexcom in some regions).
- Owned by Roche, with associated quality-management infrastructure for the regulated path.
- Clean reporting for sharing with the diabetes care team.
Limitations
- Carbohydrate accuracy depends on user entry; no photo-based portion-estimation pipeline.
- Regulatory status of the bolus advisor varies by region; users should verify the clearance status applicable to their jurisdiction.
- Some advanced features are gated behind the Pro subscription.
- Database for foods is functional but not the strongest in the segment.
Editorial summary
mySugr is the most credible integrated diabetes-logging application in the segment, and it is the application the editorial team most often recommends to T1D users who want a single-screen view of glucose, carbohydrates, and insulin. The bolus calculator is mySugr’s distinguishing feature; it is the rare consumer-facing application whose dosing aid has been routed through a regulated pathway in any major market.
The application’s carbohydrate-accuracy ceiling is bounded by the user’s portion-estimation ability. mySugr does not offer photo-based portion estimation. For users with substantial mixed-dish exposure, pairing mySugr (for the logbook and bolus support) with PlateLens (for the carbohydrate estimate) is a workable two-app workflow.
Bolus calculator and regulatory status
mySugr’s bolus calculator takes the user’s clinician-set parameters (insulin-to-carbohydrate ratio, correction factor, target range, insulin-on-board duration) and the user’s current glucose and meal carbohydrates as inputs, and produces a recommended bolus. The parameters must be set by the prescribing clinician; the application does not, and must not, recommend its own ratios or factors. The editorial team’s clinical experience is that users who configure mySugr’s bolus calculator together with their CDCES at a diabetes-education visit derive substantial value from the tool.
In several European markets the bolus advisor is registered as a medical device under the EU Medical Device Regulation (MDR). The regulatory status is region-specific, version-specific, and subject to change. Verify the current status applicable to your jurisdiction before relying on any clearance claim — for instance, by consulting your prescribing clinician or the manufacturer’s regulatory page.
In the United States, mySugr is distributed as a logbook. Users should not assume parity with the European regulated configuration without explicit confirmation.
Carbohydrate accuracy
Carbohydrate counts in mySugr are user-entered or imported from a partner application. The internal food database is functional — sufficient for typical home-cooked or pre-packaged meals — but it is not the strongest database in the segment, and there is no photo-based portion-estimation pipeline. For users with substantial mixed-dish exposure (restaurants, cafeteria, takeaway), accuracy is bounded by the user’s portion-estimation ability.
Editorial position: users with substantial mixed-dish exposure should pair mySugr (for the logbook, bolus support, and regulatory rigor) with a photo-based estimator (PlateLens at present) for the carbohydrate estimate, exporting from the estimator into mySugr. The two-app workflow is, in clinical observation, well-tolerated by users in active diabetes-education programs.
Pump and CGM integration
mySugr is owned by Roche, and the application integrates particularly cleanly with Accu-Chek pumps and meters. CGM data import varies by region; in many European markets the Abbott FreeStyle Libre integration is mature. Dexcom support is regional and version-specific.
Users on a Tandem t:slim X2 or Medtronic 780G insulin pump are unlikely to find mySugr the most natural integration partner; for those users, the pump-vendor application is typically the working tool, with mySugr or a separate carbohydrate estimator as a complementary log.
Limits
- The bolus calculator’s clinical parameters must be set by the prescribing clinician. mySugr does not recommend ratios or factors; users must not infer them from the application’s defaults.
- The CGM trend, not the bolus calculator’s recommended bolus, is the gold-standard check. If the recommended bolus disagrees with the user’s clinical judgment based on the CGM trend, the trend should generally win.
- Regional regulatory variability is real and material. The version of mySugr available in one country may not be the version available in another.
References
- Roche Diabetes Care. (2024). mySugr clinical evidence dossier (manufacturer publication; regional regulatory submission documents). Manufacturer publication.
- American Diabetes Association. (2026). Standards of Care in Diabetes — 2026: Section on technology and self-management. Diabetes Care.
- Endocrine Society. (2024). Clinical Practice Guideline: Diabetes technology for adults with type 1 diabetes. Journal of Clinical Endocrinology & Metabolism.
- Hood, K. K., et al. (2025). Bolus-calculator use and glycemic outcomes in adults with type 1 diabetes. Diabetes Technology & Therapeutics.
- Crocket, H. R., et al. (2024). Mobile bolus advisors in adolescent type 1 diabetes: an observational cohort. Pediatric Diabetes.
- Schmidt, S., et al. (2024). Real-world use of bolus calculator applications in adults with type 1 diabetes. Journal of Diabetes Science and Technology.